Courtney Marabella

Data collected from 1400 global laboratories indicate that standard immunohistochemistry testing may not be the most effective method to identify patients with breast cancer with HER2-low disease.

Patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer derived a statistically significant survival benefit following treatment with pembrolizumab and chemotherapy.

Patients with relapsed/refractory myeloma continued to experience durable and efficacious responses after treatment with ciltacabtagene autoleucel.

Patients with extensive-stage small cell lung cancer (ES-SCLC) derived overall survival benefit from a combination of durvalumab and chemotherapy.

Consistent Ki67 suppression with giredestrant was noted in a phase 2 trial versus anatrozole.

Data from the phase 3 MONALEESA-2 trial demonstrate significant benefit of frontline ribociclib (Kisqali) added to letrozole for hormone receptor–positive, HER2-negative advanced breast cancer

Investigators identified a link between high tumor mutational burden and high responses to dostarlimab among patients with endometrial cancer.

Durable efficacy and a manageable safety profile were observed with selpercatinib for Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.

Doubling treatment duration of bevacizumab did not lead to better survival in patients with ovarian cancer who were treated on a phase 3 trial.

Patients with early-stage breast cancer who have ultralow risk disease indicated by a 70-gene signature demonstrated an excellent survival prognosis regardless of clinical risk.

TG-1701 elicited promising clinical and pharmacodynamic activity across doses in patients with B-cell malignancies.

Heavily pretreated patients with relapsed/refractory B-ALL who received a single infusion of KTE-X19 experienced robust and durable responses.

Data from the OlympiA trial support olaparib use in certain patients with BRCA1/2–positive early breast cancer.

Twenty percent of patients with resectable hepatocellular carcinoma experienced significant tumor necrosis when treated with neoadjuvant cemiplimab-rwlc, according to data from a phase 2a open label.

Twice- versus once-daily dosing of investigational poziotinib for HER2 and EGFR mutations in exon 20 was more efficacious and better tolerated, according to results of the phase 2 ZENITH20 trial presented at the AACR Annual Meeting 2021.

Trastuzumab deruxtecan has not only demonstrated efficacy as a potential anti-HER2 therapeutic option for patients with HER2-amplified gastric cancers, but has also shown promise in those with HER2 moderate-, low-, and non-expressing disease.

Although responses were limited in patients with paclitaxel-pretreated cervical cancer, eribulin may still show promise in those who are naïve to treatment with the chemotherapy agent.

More cases of metastatic prostate cancer may be linked with a reduction in prostate-specific antigen screening, experts say.

A phase 2 SWOG trial comparing multiple therapies versus sunitinib for papillary renal cell carcinoma revealed superior activity of cabozantinib in this setting.

The phase 3 NeoADAURA trial will examine both single-agent osimertinib as well as the combination with platinum-based chemotherapy versus chemotherapy alone in the neoadjuvant setting in patients with resectable, stage II to IIIB non–small cell lung cancer whose tumors harbor EGFR mutations.

Safety and antitumor activity of mobocertinib became evident after results of a trial involving EGFR exon 20 insertion–mutant non–small cell lung cancer were reported at the 2020 World Conference on Lung Cancer Singapore.